Trial
NCT00214214
A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Wisconsin, Madison
Collaborators
—
Condition
New Onset Type 1 Diabetes Mellitus
Intervention
Campath 1H® (Alemtuzumab)
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-10-08